期刊文献+

奥氮平治疗对精神分裂症患者生活质量的影响 被引量:3

Effect of olanzapine on the quality of life of patients with schizophrenia
下载PDF
导出
摘要 目的:探讨奥氮平治疗精神分裂症患者对其生活质量的影响。方法:选择30例青壮年精神分裂症患者作为研究对象,所有患者均符合中国精神疾病分类与诊断标准第3版(CCMD-3)精神分裂症诊断标准,使用单一奥氮平治疗精神分裂症中,疗程11个月。观察其疗效与副作用,采用世界卫生组织简明生活质量评定量表(WHOQOL-BREF)评定精神分裂症患者使用奥氮平治疗前后的生活质量,分析量表中各领域和各方面的计分。结果:奥氮平的有效率达87%,锥体外系反应少。经治疗11个月,精神分裂症患者身体健康、心理健康、社会关系和环境因素等4个领域计分均有显著改善,分别为69.17±5.67,91.39±12.18,92.78±12.33,91.56±11.49,与治疗前比较,差异均有显著性意义(t=19.64,14.16,20.56,20.55;P均<0.01),且存在一定的时效关系,评定患者量表各领域分均显著增高。但在治疗2个月时患者对医疗的依赖仍然未得到明显改善,与治疗前相比,差异无显著性意义(t=1.98,P>0.05);用药后1个月后患者仍然认为其生活中存在信息匮乏的情况,与治疗前相比,差异无显著性意义(t=1.77,P>0.05)。结论:奥氮平治疗对改善精神分裂症患者的生活质量有积极作用。 AIM:To investigate the effect of olanzapine on the quality of life(QOL) on patients with schizophrenia. METHODS:A total of 30 adult patients with schizophrenia were selected in this study.All the cases were in accordance with the third revision of Chinese Classification of Mental Disoralers(CCMD 3).During the whole 11 month therapeutic course,only olanzapine was administered.Besides the effects and adverse effects of olanzapine,WHOQOL BREF measuring scale was used to evaluate the patients' QQL before and after administration of olanzapine,by means of analyzing the scores in every domain and facet. RESULTS:The efficiency of olanzapine was 87%,rarely with extra pyramidal side effects.After treated with olanzapine for 11 months, physical health,psychological health,social relationship,and environment of patients with schizophrenia were all significantly improved:69.17±5.67, 91.39±12.18,92.78±12.33,91.56±11.49,as compared with those before treatment,which indicated significant difference(t=19.64,14.16, 20.56,20.55;all P< 0.01).This improvement showed certain time effect relationship.Scores of every domain were all significantly increased by evaluating scale of patients.But compared with the situation before treatment, it was showed that the patients' relied on medication had not improved significantly 2 months after treatment,which indicated no significant difference (t=1.98,P >0.05);and had some complaint about information lackage in 1 month,which indicated no significant difference(t=1.77,P >0.05). CONCLUSION:Olanzapine has positive effects on QOL of patients with schizophrenia.
出处 《中国临床康复》 CSCD 2004年第18期3461-3463,共3页 Chinese Journal of Clinical Rehabilitation
  • 相关文献

参考文献14

  • 1World Health Organization WHOQOL-Brefintroduction,administration,scoring and generc version of the assessment,field trial version Programme on Mental Health. WHO:Geneva 1996:1-11
  • 2Meltzer HY, Bunett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 1990; 41: 892 - 7
  • 3Malm U, May PRA, Dencker SJ. Evaluation of the quality of life of the schizophrenic outpatient: A checklist. Schiz Bull 1981; 7:477 - 85
  • 4Lehman AF. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40:369 - 73
  • 5Heinrichs DW. Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388 -98
  • 6Mulkern VM, Manderscheid RW. Characteristics of community support program clients in 1980 and 1984. Hosp Comm Psychiatry 1989; 40:165 -72
  • 7Bobes J, Gonzalez MP. Quality of life in schizophrenia∥Katschnig H, Freeman H, Sartorius N. Quality of Life in Mental Disorders. Chichester: John Wiley Sons 1997:56 -211
  • 8Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics(risperidone or olanzapine) in elderly patients with schizophrenia. Int J Ge
  • 9Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61 (1): 111 - 61
  • 10Bymaster FP, Calligaro do, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsyclupharmacology 1996; 14(2): 87

二级参考文献11

共引文献58

同被引文献16

  • 1杨小男,梅其一.奥氮平与利培酮治疗首发精神分裂症对照研究[J].上海精神医学,2003,15(6):338-340. 被引量:5
  • 2杨献红,黄继忠,严和骎,江开达,陆峥,盛尤荣,熊祥玉,冯明德,姚维菊,吴敏.奥氮平治疗精神分裂症70例临床分析[J].上海精神医学,2002,14(2):94-96. 被引量:26
  • 3杨忠,潘凤英,尹建兵,宋静波,谭文钟.国产和进口奥氮平治疗首发精神分裂症的疗效分析[J].神经疾病与精神卫生,2006,6(5):345-346. 被引量:3
  • 4Long J, Huang G, Liang W, et al. The prevalence of schizophrenia in China's Mainland: evidence from epidemiological surveys. Acta Psychiatr Seand. 2014 Jun 11.
  • 5何燕玲.阳性与阴性症状量表(PANSS)[J].中国心理卫生杂志(增刊),1999:267-275.
  • 6向东,王希林,马弘.心理卫生评定量表手册(增订版)[J].中国心理卫生杂志,1999,12(增):88-100;127-131.
  • 7Liu - Seifert H, Osuntokun O0, Feldman PD. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia [ J ]. Compr Psychiatry,2012,53 ( 1 ) : 107-115.
  • 8Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double - blind clozapine, olanzapine or haloperidol [ J ]. Schizophr Res,2009,110 ( 1 - 3 ) :95-102.
  • 9de Ara'ajo AA1, de Arat-jo Dantas D, et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio - economic Factors and Adverse Effects of Atypical Antipsychotics Drugs[J]. Psychiatr Q. 2014 May 1.
  • 10汪艳,蔡丽伟,张红星,杜波,金超,阎浩,李玲芝,刘琦,闫俊,马文斌,栗克清,吕路线,张鸿燕,岳伟华,张岱,王力芳.氟哌啶醇与奥氮平治疗精神分裂症疗效和安全性的随机对照研究[J].中国神经精神疾病杂志,2012,38(4):217-221. 被引量:47

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部